MX2018006155A - Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. - Google Patents
Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.Info
- Publication number
- MX2018006155A MX2018006155A MX2018006155A MX2018006155A MX2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A
- Authority
- MX
- Mexico
- Prior art keywords
- state form
- solid state
- methods
- piridine
- pladienolide
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- -1 pyridine compound Chemical class 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente descripción proporciona una forma en estado sólido novedosa de compuesto de pladienolida piridina, composiciones que comprenden al menos una forma en estado sólido y métodos de preparación y uso de los mismos. La forma en estado sólido novedosa de compuestos de pladienolida piridina puede ser útil en el tratamiento de cáncer, tal como, por ejemplo, cánceres en los que los agentes que se dirigen a espliceosoma y las mutaciones de las mismas son conocidos siendo útiles.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257088P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062525 WO2017087667A1 (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018006155A true MX2018006155A (es) | 2018-08-01 |
| MX379655B MX379655B (es) | 2025-03-11 |
Family
ID=57472076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001441A MX392475B (es) | 2015-11-18 | 2016-11-17 | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso |
| MX2018006155A MX379655B (es) | 2015-11-18 | 2016-11-17 | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001441A MX392475B (es) | 2015-11-18 | 2016-11-17 | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10745387B2 (es) |
| EP (1) | EP3377485B1 (es) |
| JP (2) | JP6312282B2 (es) |
| KR (1) | KR20180083376A (es) |
| CN (1) | CN108473479B (es) |
| AU (2) | AU2016357433B2 (es) |
| BR (1) | BR112018009995B1 (es) |
| CA (1) | CA3004623C (es) |
| ES (1) | ES2757174T3 (es) |
| IL (1) | IL259198B2 (es) |
| MD (1) | MD3377485T2 (es) |
| MX (2) | MX392475B (es) |
| RU (2) | RU2743349C2 (es) |
| SG (2) | SG10201913045PA (es) |
| WO (1) | WO2017087667A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019199667A2 (en) * | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
| JP7334181B2 (ja) | 2018-04-12 | 2023-08-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癌治療用のスプライセオソームターゲティング薬剤としてのプラジエノライド誘導体 |
| AU2019279012A1 (en) * | 2018-06-01 | 2020-12-24 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| WO2021113755A2 (en) * | 2019-12-04 | 2021-06-10 | Pai Athma A | Anti-slc6a1 oligonucleotides and related methods |
| WO2021248005A1 (en) * | 2020-06-05 | 2021-12-09 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| CA3199753A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI311558B (en) * | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| BR0316746A (pt) | 2002-11-29 | 2005-10-18 | Mercian Corp | Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) |
| CA2546614A1 (en) | 2003-11-27 | 2005-06-09 | Mercian Corporation | Dna participating in hydroxylation of macrolide compound |
| JP4695982B2 (ja) | 2003-11-28 | 2011-06-08 | 財団法人神奈川科学技術アカデミー | 肝癌の検出方法及び肝癌診断薬並びに癌治療薬 |
| WO2006003706A1 (ja) | 2004-07-02 | 2006-01-12 | Plus One Techno & Co., Ltd. | 組み合わせ計量技術 |
| WO2006009276A1 (ja) | 2004-07-20 | 2006-01-26 | Eisai R & D Management Co., Ltd. | プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ |
| TW200716744A (en) | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| CN101282967B (zh) | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| JPWO2008111464A1 (ja) * | 2007-03-05 | 2010-06-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| KR101710318B1 (ko) * | 2014-05-15 | 2017-02-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 플라디에놀리드 피리딘 화합물 및 사용 방법 |
-
2016
- 2016-11-17 IL IL259198A patent/IL259198B2/en unknown
- 2016-11-17 WO PCT/US2016/062525 patent/WO2017087667A1/en not_active Ceased
- 2016-11-17 CA CA3004623A patent/CA3004623C/en active Active
- 2016-11-17 BR BR112018009995-3A patent/BR112018009995B1/pt active IP Right Grant
- 2016-11-17 CN CN201680067749.5A patent/CN108473479B/zh active Active
- 2016-11-17 MX MX2021001441A patent/MX392475B/es unknown
- 2016-11-17 MX MX2018006155A patent/MX379655B/es unknown
- 2016-11-17 AU AU2016357433A patent/AU2016357433B2/en active Active
- 2016-11-17 MD MDE20180923T patent/MD3377485T2/ro unknown
- 2016-11-17 SG SG10201913045PA patent/SG10201913045PA/en unknown
- 2016-11-17 ES ES16805664T patent/ES2757174T3/es active Active
- 2016-11-17 EP EP16805664.6A patent/EP3377485B1/en active Active
- 2016-11-17 RU RU2018121610A patent/RU2743349C2/ru active
- 2016-11-17 SG SG11201803519YA patent/SG11201803519YA/en unknown
- 2016-11-17 RU RU2021102393A patent/RU2021102393A/ru unknown
- 2016-11-17 KR KR1020187016598A patent/KR20180083376A/ko active Pending
- 2016-11-17 US US15/529,798 patent/US10745387B2/en active Active
- 2016-11-17 JP JP2017528992A patent/JP6312282B2/ja active Active
-
2018
- 2018-03-16 JP JP2018049098A patent/JP6353620B1/ja active Active
-
2020
- 2020-07-17 US US16/932,627 patent/US20200361915A1/en not_active Abandoned
-
2021
- 2021-02-15 AU AU2021200974A patent/AU2021200974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018006155A (es) | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. | |
| DOP2019000266A (es) | Inhibidores de pd-1/pd-l1 | |
| CL2017001040A1 (es) | Métodos para tratar infecciones por el virus filoviridae | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| UY36950A (es) | Compuestos útiles como inhibidores de la interacción proteína-proteína pd-1/pd-l1 y cd80/pd-l1 y composiciones que los contienen | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| CO2017013408A2 (es) | Compuestos bicíclicos heterocíclicos como agentes antituberculares. | |
| MX2016011619A (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| UY36076A (es) | Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen. | |
| MX2016010216A (es) | Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos. | |
| CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| MX390537B (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| UY36075A (es) | Derivados de tubulisina | |
| CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos | |
| CL2018000098A1 (es) | Composiciones de plinabulina. | |
| MX373324B (es) | Compuestos piridínicos de pladienolida y métodos de uso. | |
| CL2017001336A1 (es) | Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos | |
| CR20160016A (es) | Pirazolpiridinas sustituidas |